To buy shares in Innate Pharma S.A. ADS you will need a US based stock trading platform like Interactive Brokers or Moomoo where it currently costs $1.37 to buy one share in Innate Pharma S.A. ADS (as of 16:00 02-Apr-2026). Which is a change of $0.02 or 1.48% from the last closing price of $1.35.
How To Buy Innate Pharma S.A. ADS Stock
It may seem complicated to buy stock for the first time, but it’s actually very easy. Follow these simple steps to buy shares in Innate Pharma S.A. ADS:
- Pick a stock broker (jump down to compare the best brokers for buying Innate Pharma S.A. ADS stock)
- Deposit funds (bank transfer, ACH, wire transfer, or card)
- Search for the stock symbol: (NASDAQ:IPHA)
- Choose the number of shares you want to buy (1 share currently costs $1.37)
- Click buy (you can either trade immediately at “market” or set a “limit” to buy the stock cheaper if you think the price will go down)
- Track the performance of your Innate Pharma S.A. ADS stock in your account (this will show your profit and loss)
- Innate Pharma S.A. ADS is currently worth $123,557,245 based on the last closing price of $1.35 with 17,252 shares traded.
- The most recent Innate Pharma S.A. ADS daily high has been $1.4 and daily low $1.33.
- The Innate Pharma S.A. ADS stock price 52 week high has been $2.63 and the 52 week low $1.17.
Compare Brokers For Buying Innate Pharma S.A. ADS Stock
Is Now A Good Time To Buy Innate Pharma S.A. ADS Stock?
- Innate Pharma S.A. ADS’s EPS (earnings per share) are 0.64. A high EPS indicates strong profitability but may already be priced in, while a low EPS could signal weak earnings or a turnaround opportunity, requiring industry comparison.
- Innate Pharma S.A. ADS’s PE (price earnings ratio) is n/a. A low PE ratio may suggest undervaluation but could also indicate slow growth or risk, whereas a high PE ratio reflects high growth expectations but may signal overvaluation, necessitating a check on earnings sustainability.
The below Innate Pharma S.A. ADS share price analysis and market data includes key financials, earnings estimates, peer performance, dividends, news and a company profile that will give you an indication as to whether this stock is a buy, sell or hold. Subscribe to Good Money Guide Analysis for expert opinion on the latest investment opportunities.